Global Diagnostics scans first PSMA patient in Bunbury
On Thursday 11 July 2019 Global Diagnostics scanned their first PSMA PET CT patient at South West Health Campus in Bunbury. GDA is now offering two new PET CT Studies, Whole body 68Ga DOTA peptide PET study and Whole body 68Ga PSMA peptide PET study.
Whole body 68Ga PSMA peptide PET study is a special type of test used to image prostate cancer that has demonstrated excellent sensitivity in detection of low volume prostate cancer cells throughout the body. They are performed on newly diagnosed prostate cancer patients to determine if the disease has spread, making it an active tool in the patients’ treatment plan.
PSMA stands for Prostate Specific Membrane Antigen. It is a type 2 membrane protein found in all forms of prostate tissue, including carcinoma. The PET CT scans the whole body and provides highly detailed information about the presence or current state of disease, as well as its precise location.
Whole body 68Ga DOTA peptide PET study is used to identify neuroendocrine tumours (NETs). NETs are known to have a receptor upon the surface of the tumour cell, known as somatostatin receptors. Ga68 (Gallium 68) DOTATATE PET/CT utilises a molecule that attaches to this receptor on the surface of the NET cells. This DOTATATE molecule is bound to the radionuclide Ga68. Ga68 emits gamma radiation which is detected by a PET/CT scanner. This enables us to image the distribution of any cancer within the body.
Congratulations to Rod Stacey, Nuclear Medicine Services Manager, who was instrumental in establishing this service for the community of the South West.